Altria's juicy dividend lures amid cigarette decline, but smoke-free pivot lags rivals
Company Snapshot
Altria Group, Inc. manufactures and sells smokeable and oral tobacco products in the United States, including Marlboro cigarettes, Black & Mild cigars, Copenhagen and Skoal smokeless tobacco, on! nicotine pouches, and NJOY e-vapor products.
Executive Brief
The bull case for Altria rests on its dominant U.S. market position with Marlboro commanding over 40% cigarette share, unmatched pricing power offsetting 8-10% annual volume declines, and robust free cash flow of $8B+ supporting a 6.5%+ dividend yield with 55+ years of increases plus $2B buybacks. Transition to smoke-free products like on!
pouches and NJOY vapes positions it for nicotine market growth, with oral segment up to 12% of revenue and high 40%+ margins driving EPS growth to $5.56-$5.72 in 2026. Bear case highlights persistent cigarette shipment drops, lagging in explosive pouch growth versus Philip Morris' Zyn due to regulatory hurdles and illicit competition eroding share, plus past diversification failures like Juul writedowns straining balance sheet. Key risks include stricter FDA regulations on nicotine products, escalating litigation from health claims, and failure to scale smoke-free alternatives amid shifting consumer preferences away from tobacco.
Recent Catalysts
- on! PLUS expands nationwide, wholesale Mar 16
- Declares $1.06 quarterly dividend, ex-Mar 25
- Reaffirms 2026 EPS $5.56-$5.72 at CAGNY conf
Key Risks
- Declining cigarette volumes 8-10% annually
- Regulatory bans on menthol, flavors
- Competition from illicit vapes, pouches
Full Research Report
Get our research reports in your inbox
New reports and product updates. Unsubscribe anytime.